Swiss - Delayed Quote CHF

Basilea Pharmaceutica AG (BSLN.SW)

Compare
42.10
-0.75
(-1.75%)
At close: January 10 at 5:30:32 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BSLN.SW

Recent News: BSLN.SW

View More
Basilea provides portfolio update and outlook

Basilea provides portfolio update and outlook
GlobeNewswire 3 days ago
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
GlobeNewswire 19 days ago
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewswire 26 days ago
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
GlobeNewswire 3 months ago
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
GlobeNewswire 3 months ago
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
GlobeNewswire 4 months ago
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
GlobeNewswire 4 months ago
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
GlobeNewswire 4 months ago
Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why

Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why
Zacks 4 months ago
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance

Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
GlobeNewswire 4 months ago
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire 6 months ago
View More

Related Tickers

ORN.F Oryzon Genomics S.A.
1.5020
+2.18%
 
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
 
7IZ.MU Ziccum AB
0.0298
-29.72%
 
5KW.F SkinBioTherapeutics plc
0.1720
+1.18%
 
PH4.F CStone Pharmaceuticals
0.2640
-1.49%
 
VSC.F 4SC AG
5.50
-3.85%
 
4AJ0.SG Alk-Abello A/S
19.46
+0.46%
 
41X.F Ardelyx, Inc.
5.12
+0.16%
 
XRP2.F Silence Therapeutics plc
5.95
+0.85%
 
BLE.BE bluebird bio Inc
0.3708
-3.01%